LIM
VRTX icon

Longfellow Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Longfellow Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13
Closed -$5.09K – 270
2025
Q3 		$5.09K Buy
13
+7
+117% +$2.92K ﹤0.01% 190
2025
Q2 		$2.67K Hold
6
– – ﹤0.01% 213
2025
Q1 		$2.91K Hold
6
– – ﹤0.01% 213
2024
Q4 		$2.42K Hold
6
– – ﹤0.01% 224
2024
Q3 		$2.79K Hold
6
– – ﹤0.01% 207
2024
Q2 		$2.81K Hold
6
– – ﹤0.01% 201
2024
Q1 		$2.51K Hold
6
– – ﹤0.01% 222
2023
Q4 		$2.44K Buy
+6
New +$2.22K ﹤0.01% 200

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Longfellow Investment Management's VRTX Position: Q4 2025 in Review

Longfellow Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 13 shares — an estimated $5.09K sold.

Longfellow Investment Management first reported a position in VRTX in Q4 2023 and held it in 8 quarters. The position peaked at $5.09K in Q3 2025. 1,671 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Longfellow Investment Management reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Longfellow Investment Management sold 13 Vertex Pharmaceuticals shares in Q4 2025, an estimated $5.09K.
  • Longfellow Investment Management first reported a position in Vertex Pharmaceuticals in Q4 2023 and held it in 8 quarters.
  • Longfellow Investment Management's Vertex Pharmaceuticals position peaked at $5.09K in Q3 2025.
  • 1,671 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Longfellow Investment Management's 13F filing for Q4 2025, filed 11 Feb 2026.